If it wasn't obvious before, Latigo Biotherapeutics is all in on its non-opioid pain treatment pipeline and that is highlighted further by the company's $150 million Series B capital raise. Announced ...
Weeks after KSAT’s Know My Neighborhood series highlighted safety concerns on a street in Denver Heights, the City of San ...
The Food and Drug Administration has granted Fast Track designation to LTG-001 for the treatment of acute pain.
Latigo Biotherapeutics, Vivace Therapeutics, and Vori Health each announced the recent successful closing of their respective ...
A Texas state trooper accused of wrongfully killing a man in Converse after a pursuit exercised his right to remain silent ...
California-based Latigo Biotherapeutics, a biotech developing non-opioid pain treatments, has closed $150 million in a Series B financing.
Latigo Biotherapeutics has secured $150m in a Series B financing round, which will be used to further the development of its ...
From STAT’s Andrew Joseph: AstraZeneca said this morning it was buying the Belgian cell therapy company EsoBiotec for $425 million upfront, building out another cancer-targeting approach.
The round, which included more than a dozen investment firms, should give the startup enough cash to get late-stage data for ...
Latigo Biotherapeutics has tapped into investor interest in pain relief medicines with new, non-opioid mechanisms of action, ...
Latigo Biotherapeutics ("Latigo"), a clinical-stage biotechnology company developing best-in-class non-opioid pain treatments ...
Latigo Biotherapeutics has whipped together a $150 million series B fundraising round to advance a pipeline of non-opioid ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback